Freedom Broker has also upgraded the stock from Hold to Buy, raising its price target to $37.00, citing improved mid-term revenue prospects due to the resumed supply of Elevidys. Meanwhile, TD Cowen maintained its Hold rating with a $17.00 target after Sarepta's webinar revealed similar risks of acute liver injury for both ambulatory and non-ambulatory patients. BMO Capital continues to rate Sarepta at Market Perform with a $50.00 target, noting that the company expects normal commercial dynamics by the fourth quarter. Additionally, Wells Fargo increased its price target to $50.00, maintaining an Overweight rating, as Sarepta progresses in its siRNA programs in collaboration with Arrowhead Pharmaceuticals. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.